| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | IGFBP-3|IGFBP3|BP-53|IBP3 |
| Assay Time | |
| Detection Method | |
| Detection Range | |
| Product Type | |
| Reactivity | |
| Sample Type(s) | Serum, Plasma, Cell Culture Supernatant, cell or tissue lysate, Other liquid samples |
| Sensitivity | |
| Species | |
| Storage | |
| Target | |
| UniProt # |
Background
human IGFBP-3 (Insulin-like growth factor-binding protein 3) is a molecular target commonly studied in immunology, signal transduction, and cardiovascular research. Growth factors are signaling proteins that influence proliferation, differentiation, and tissue remodeling through receptor activation.
Biological role and mechanism
The biological role of IGFBP-3 is typically understood in terms of its molecular category and interaction network. Depending on the model system, it may participate in cell–cell communication, intracellular signaling, enzymatic processing, or regulation of gene expression programs. Mechanistic interpretation is often strengthened by considering upstream regulators and downstream readouts rather than relying on a single marker.
Expression and abundance of IGFBP-3 can vary by tissue, cell type, and physiological state. In many systems, levels are influenced by factors such as developmental stage, immune activation, metabolic status, and cellular stress. Because sample matrix and pre-analytical handling can affect measured concentrations, interpretation is typically strongest when experiments keep collection and processing consistent across groups.
Nomenclature and related terms
IGFBP-3 (Insulin-like growth factor-binding protein 3) may also be referenced as IGFBP-3, IGFBP3, and BP-53 in the literature or in databases. When comparing results across studies, confirm that the reported analyte refers to the same molecule, species context, and molecular form (e.g., precursor vs mature protein, or soluble vs membrane-associated forms).
Why it matters in research
- Understanding how IGFBP-3 relates to innate and adaptive immune responses, cytokine signaling networks, host–pathogen interactions, and immune cell activation and trafficking in immunology, signal transduction, and cardiovascular research.
- Interpreting shifts in IGFBP-3 levels alongside other pathway components or complementary markers.
- Connecting molecular changes to phenotypes such as inflammation, remodeling, metabolism shifts, or cell-state transitions (context-dependent).
Molecular forms and interpretation
For some targets, isoforms, proteolytic processing, or post-translational modifications (such as phosphorylation or glycosylation) can influence function and apparent abundance. If multiple molecular forms are expected in your model, align interpretation with the form most relevant to the biological question.
Disease and translational relevance
IGFBP-3 has been investigated across diverse physiological and disease contexts, and changes in its abundance have been reported in areas aligned with immunology, signal transduction, and cardiovascular studies. These associations are interpreted as research findings rather than diagnostic or therapeutic claims, and they should be evaluated alongside model-specific covariates and study design.
Can’t Find What You’re Looking For? We can help you source the best match or customize an ELISA solution for your study. Options may include alternative target synonyms, different species reactivity, sample type/matrix compatibility (serum/plasma/lysate/supernatant), assay format (sandwich/competitive), sensitivity/range, detection chemistry (colorimetric/fluorescent/chemiluminescent), plate format (pre-coated/uncoated, strips vs full plate), and bulk or custom packaging. Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.
Protein Plasma Levels of the IGF Signalling System Are Altered in Major Depressive Disorder
IF: 5.6 Journal: International Journal of Molecular Sciences Author: Translational Neuroscience Group, Galicia Sur Health Research Institute (IIS Galicia Sur), ?rea Sanitaria de Vigo-Hospital ?lvaro Cunqueiro, SERGAS-UVIGO, CIBERSAM-ISCIII, 36213 Vigo, Spain Cited Date: 2023-10-20
Plasma Insulin-like growth factor binding protein 3 (IGFBP-3) and IGFBP-5 are decreased during acute manic episodes in bipolar disorder
IF: 5.6 Journal: Frontiers in Pharmacology Author: Instituto de Investigación Sanitaria Galicia Sur (IISGS), Vigo, Spain Cited Date: 2024-03-22
Plasma IGFBP-3 and IGFBP-5 levels are decreased during acute manic episodes in bipolar disorder patients
IF: 4.8 Journal: Frontiers in Pharmacology Author: Translational Neuroscience Group, Galicia Sur Health Research Institute (IIS Galicia Sur), área Sanitaria de Vigo-Hospital álvaro Cunqueiro, SERGAS-UVIGO, CIBERSAM-ISCIII, Vigo, Spain. Cited Date: 2025-10-17
A novel serum protein biomarker for the late-stage diagnosis of nasopharyngeal carcinoma
IF: 3.4 Journal: BMC Cancer Author: Department of Laboratory Medicine, The Eighth Affiliated Hospital, Sun Yat-Sen University, Shenzhen, 518033, China. Cited Date: 2025-04-11
Serum HIF-1α, IGF-1 and IGFBP-3 correlate to recurrence and overall survival in early-stage hepatocellular carcinoma patients
IF: 1.9 Journal: Biomarkers in Medicine Author: Department of Ultrasonography, Wuxi People's Hospital Affiliated to Nanjing Medical University, Qingyang Road, Wuxi, 214023, Jiangsu, China. Cited Date: 2024-11-29